Carubelli Valentina, Lombardi Carlo, Gorga Elio, Ravera Alice, Metra Marco, Mentz Robert J
Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, P.zza Spedali Civili 1, Brescia 25123, Italy.
Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, P.zza Spedali Civili 1, Brescia 25123, Italy.
Heart Fail Clin. 2016 Jul;12(3):335-47. doi: 10.1016/j.hfc.2016.03.002.
Recently, there has been increased appreciation of the identification and management of comorbidities in heart failure patients, and for therapies targeting conventional heart failure signs and symptoms. Renal dysfunction is common in patients with heart failure and is associated with high morbidity and mortality. Early identification of renal damage through novel biomarkers and the use of new pharmacological strategies aimed at preserving renal function may represent an important objective in the treatment. This article reviews the epidemiology and pathophysiology of cardiorenal syndrome in heart failure, and highlights novel biomarkers and improved therapies targeting renal dysfunction.
近年来,人们越来越重视心力衰竭患者合并症的识别与管理,以及针对传统心力衰竭体征和症状的治疗方法。肾功能不全在心力衰竭患者中很常见,且与高发病率和高死亡率相关。通过新型生物标志物早期识别肾损伤,并采用旨在保护肾功能的新药理学策略,可能是治疗中的一个重要目标。本文综述了心力衰竭中心肾综合征的流行病学和病理生理学,并重点介绍了针对肾功能不全的新型生物标志物和改进疗法。